梅花生物(600873) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 reached CNY 3,974,564,421.68, an increase of 19.06% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 245,564,396.27, a decrease of 28.14% year-on-year[4] - Basic earnings per share were CNY 0.08, a decrease of 27.27% compared to CNY 0.11 in the same period last year[4] - Operating profit for Q1 2020 was ¥303,982,156.66, a decrease of 26.4% compared to ¥413,113,446.80 in Q1 2019[22] - Net profit for Q1 2020 was ¥248,574,140.83, down 28.3% from ¥346,259,457.68 in Q1 2019[22] - Total comprehensive income for Q1 2020 was CNY 22,658,760.84, compared to CNY 52,044,573.76 in Q1 2019, showing a significant decrease[26] Cash Flow - Net cash flow from operating activities decreased by 48.53% to CNY 148,825,306.42 compared to the previous year[4] - Cash flow from operating activities for Q1 2020 was CNY 148,825,306.42, down from CNY 289,163,110.76 in Q1 2019, indicating a decrease of 48.6%[27] - The net cash flow from operating activities for Q1 2020 was -17,494,612.57 RMB, a significant decrease compared to 276,378,952.47 RMB in Q1 2019[29] - Total cash inflow from operating activities was 2,245,925,630.64 RMB, down from 3,570,546,140.53 RMB year-over-year[29] - Cash outflow from operating activities totaled 2,263,420,243.21 RMB, compared to 3,294,167,188.06 RMB in the same period last year[29] Assets and Liabilities - The total assets at the end of the reporting period were CNY 18,764,401,140.62, down 2.86% from the end of the previous year[4] - Total assets decreased from 19,317,701,400.77 to 18,764,401,140.62, a decline of approximately 2.85%[16] - Total liabilities decreased from 10,101,166,362.05 to 9,352,009,653.15, a decline of about 7.41%[17] - Current liabilities decreased from 5,457,239,457.24 to 4,684,518,921.40, a reduction of about 14.14%[17] - Total equity attributable to shareholders increased from 8,979,234,137.96 to 9,172,080,842.15, an increase of approximately 2.16%[17] Expenses - Financial expenses increased by 58.81% to ¥83.85 million, primarily due to increased exchange losses[11] - The company reported a significant increase in sales expenses to ¥309,362,149.86 from ¥265,783,449.91, an increase of 16.3%[21] - Tax expenses decreased to ¥43,881,697.40 from ¥53,604,672.64, a reduction of 18.1%[21] - Research and development expenses surged by 893.78% to ¥60.59 million, attributed to increased R&D investments at new bases[11] Shareholder Information - The number of shareholders at the end of the reporting period was 135,277, with the largest shareholder holding 27.51% of the shares[7] - The company repurchased 45,847,603 shares, accounting for 1.48% of total share capital, with an average repurchase price of ¥4.384 per share[12] Future Outlook - Future outlook includes potential market expansion and new product development initiatives[4]